

Meeting Minutes

Institution:	Children’s Hospital of Orange County (CHOC)		
Meeting Date:	December 17, 2025		
Meeting Time	11:00 AM Pacific Time		
Meeting Type:	Virtual Platform Teleconference (Remote) Open to the Public		
Members in Attendance:	Member	Voting	Member Type
	Bavaret, Tammy	Yes	Chair: Biosafety Expert/HGT Expert
	Ellis, Robert	Yes	Core Member: Biosafety Expert/HGT Expert
	Rastein, Daniel	Yes	Core Member: Biosafety Expert/HGT Expert
	De Zoysa, Prashan	Yes	Local Unaffiliated Member
	Lally, Rebecca	Yes	Local Unaffiliated Member
	Larson, Krista	No	Site Contact
Invited Members Not in Attendance:	Member	Voting	Member Type
	None		
Guests:	Han, Eugenie Fernandez, Nubia Stockton, Winnie		
Staff:	Hemmelgarn, Marian		

Call to Order: The IBC Chair called the meeting to order at 11:00 AM. A quorum was present as defined in the Sabai IBC Charter.

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

Public Comments: No public comments were made prior to or at the meeting.

Review of Prior Business: None

Previous Meeting Minutes: Minutes from 7/29/25 were approved by the IBC with no changes.

New Business:

PI:	Al-Hertani, Walla MD, MSc, FRCPC, FCCMG, FACMG
Sponsor:	Beam Therapeutics Inc.
Protocol:	BTX-301-001 A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients with Glycogen Storage Disease Type Ia (GSDIa) Homozygous or Compound Heterozygous for the G6PC1 c.247C>T (p.R83C) Variant
Review Type:	Change in Research Review
NIH Guidelines Section:	III-C-1

Trial Summary: BTX-301-001 is an open-label, single-ascending-dose, Phase I/II study sponsored by Beam Therapeutics Inc. and designed to evaluate the safety and efficacy of BEAM-301, a lipid nanoparticle encapsulating a messenger RNA encoding an adenine base editor and guide RNA targeting a pathogenic allele variant of G6PC1, in participants with Glycogen storage disease type Ia (GSDIa) homozygous or compound heterozygous for the p.R83C variant. The investigational product (IP) is administered by intravenous infusion.

Biosafety Containment Level (BSL): Because the study agent consists of synthetic mRNA incapable of replication and does not encode for known hazardous transgenes, BSL-1 containment may be considered as the minimum biocontainment level. The administration of this agent in a clinical setting requires compliance with the OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030).

Risk Assessment and Discussion:

- The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
 - In summary, the primary risks in this clinical trial include potential occupational exposure from accidental needlesticks, spills or splashes of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices (including Standard Precautions and sharps safety) and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
 - The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
 - The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
 - The Site confirmed that staff members receive Bloodborne Pathogens training.

Meeting Minutes

- Occupational Health Recommendations: None
- The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.
- The Committee reviewed the Site's facility details, relevant study-specific procedures and practices the PI's credentials and other applicable information provided by the Site for the purposes of the IBC review.
 - The Chair reviewed the Change in Research (CIR) proposed by the Site. The Site is adding a new pharmacy as a backup storage and preparation location with biosafety cabinets and removing the previous backup preparation room/biosafety cabinet. The Site noted that they have received approval from the Board of Pharmacy and the California Department of Public Health and the new pharmacy is now operational.
 - The Site verified that the information provided by the Chair was accurate.

Motion: A motion of Full Approval for the study at BSL-1 plus Standard Precautions was passed by unanimous vote.

- Contingencies stated by the Committee: None
- Stipulations stated by the Committee: None

Review of Incidents: Nothing to report.

IBC Training: Nothing to report.

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 11:19AM

Post-Meeting Pre-Approval Note: None